Rapid response to mycophenolate mofetil in combination with romiplostim in a case of severe refractory immune thrombocytopenia post COVID-19 vaccination

Snigdha Nutalapati; Garima Gupta; Gerhard C. Hildebrandt

doi:10.1002/ccr3.5035

Rapid response to mycophenolate mofetil in combination with romiplostim in a case of severe refractory immune thrombocytopenia post COVID-19 vaccination

Snigdha Nutalapati, Garima Gupta, Gerhard C. Hildebrandt

Producción científica: Article › revisión exhaustiva

1 Cita (Scopus)

Resumen

Vaccine mediated immune mediated thrombocytopenia (ITP) is exceedingly rare. We present a case of a young female who developed severe refractory ITP with multiple bleeding sites post second dose of COVID-19 vaccination. She was treated with a combination of romiplostim and mycophenolate mofetil that resulted in rapid platelet count recovery.

Idioma original	English
Número de artículo	e05035
Publicación	Clinical Case Reports
Volumen	9
N.º	11
DOI	https://doi.org/10.1002/ccr3.5035
Estado	Published - nov 2021

Nota bibliográfica

Publisher Copyright:
© 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.

ASJC Scopus subject areas

General Medicine

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Acceder al documento

10.1002/ccr3.5035

Otros archivos y enlaces

Citar esto

@article{3cdfd8a2b7514cbf83850aeb759b0919,

title = "Rapid response to mycophenolate mofetil in combination with romiplostim in a case of severe refractory immune thrombocytopenia post COVID-19 vaccination",

abstract = "Vaccine mediated immune mediated thrombocytopenia (ITP) is exceedingly rare. We present a case of a young female who developed severe refractory ITP with multiple bleeding sites post second dose of COVID-19 vaccination. She was treated with a combination of romiplostim and mycophenolate mofetil that resulted in rapid platelet count recovery.",

keywords = "SARS-CoV2 vaccination, immune thrombocytopenia, mycophenolate mofetil, romiplostim",

author = "Snigdha Nutalapati and Garima Gupta and Hildebrandt, \{Gerhard C.\}",

note = "Publisher Copyright: {\textcopyright} 2021 The Authors. Clinical Case Reports published by John Wiley \& Sons Ltd.",

year = "2021",

month = nov,

doi = "10.1002/ccr3.5035",

language = "English",

volume = "9",

number = "11",

}

TY - JOUR

T1 - Rapid response to mycophenolate mofetil in combination with romiplostim in a case of severe refractory immune thrombocytopenia post COVID-19 vaccination

AU - Nutalapati, Snigdha

AU - Gupta, Garima

AU - Hildebrandt, Gerhard C.

PY - 2021/11

Y1 - 2021/11

N2 - Vaccine mediated immune mediated thrombocytopenia (ITP) is exceedingly rare. We present a case of a young female who developed severe refractory ITP with multiple bleeding sites post second dose of COVID-19 vaccination. She was treated with a combination of romiplostim and mycophenolate mofetil that resulted in rapid platelet count recovery.

AB - Vaccine mediated immune mediated thrombocytopenia (ITP) is exceedingly rare. We present a case of a young female who developed severe refractory ITP with multiple bleeding sites post second dose of COVID-19 vaccination. She was treated with a combination of romiplostim and mycophenolate mofetil that resulted in rapid platelet count recovery.

KW - SARS-CoV2 vaccination

KW - immune thrombocytopenia

KW - mycophenolate mofetil

KW - romiplostim

UR - http://www.scopus.com/inward/record.url?scp=85119969760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85119969760&partnerID=8YFLogxK

U2 - 10.1002/ccr3.5035

DO - 10.1002/ccr3.5035

M3 - Article

AN - SCOPUS:85119969760

VL - 9

JO - Clinical Case Reports

JF - Clinical Case Reports

IS - 11

M1 - e05035

ER -

Rapid response to mycophenolate mofetil in combination with romiplostim in a case of severe refractory immune thrombocytopenia post COVID-19 vaccination

Resumen

Nota bibliográfica

ASJC Scopus subject areas

ODS de las Naciones Unidas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto